Track and field athletes often look at growth hormone secretagogues for recovery and lean mass support. Hexarelin and CJC-1295 are two of the most discussed options in that space. This article compares them for muscle growth, using published research on performance and rehab peptides. We do not endorse or recommend the use of any peptide for any purpose other than legitimate research.
What this comparison covers
Both compounds increase growth hormone release, but they do it through different mechanisms and timelines. Hexarelin is a synthetic GHRP that binds the ghrelin receptor. CJC-1295 is a modified GHRH analogue with a longer half-life. The practical question for athletes is which one supports lean mass better.
Research on these peptides comes mostly from animal models and small human trials. The literature on GHRPs and GHRH analogues suggests that pulse pattern matters. A sharp spike may help fat loss, while a sustained elevation may favor tissue repair. That distinction drives the comparison.
Key compounds in this area
Hexarelin is a hexapeptide, a short chain of six amino acids. It was developed in the 1990s as a more stable alternative to GHRP-6. It triggers GH release within 15 to 30 minutes after administration. The effect lasts a few hours, then returns to baseline.
CJC-1295 is a 30-amino acid peptide. It binds to albumin in the blood, which extends its half-life to several days. A single dose can keep GH levels elevated for up to a week in some studies. That makes it a once or twice weekly research compound, not a daily one.
Other peptides appear in this conversation. MK-677 is an oral ghrelin mimetic with a 24-hour effect. IGF-1 LR3 is a direct growth factor, not a secretagogue. BPC-157 is a healing peptide with no direct GH action. GHRP-6 is the older, shorter-acting cousin of Hexarelin. Each has a different role in the recovery stack.
What the research consensus looks like
Published research shows that Hexarelin increases GH and IGF-1 in a dose-dependent way. A 2019 trial in healthy adults found a peak GH response around 30 minutes after injection. The same trial noted that repeated daily dosing led to some desensitization. That means the pituitary responds less over time.
CJC-1295 produces a slower, longer elevation. A 2022 review of GHRH analogues described its effect as a continuous infusion rather than a pulse. That pattern keeps IGF-1 higher for days. The review also noted that CJC-1295 does not blunt the body's own GH pulses the way some long-acting secretagogues do.
For muscle growth, the literature on GH secretagogues suggests that IGF-1 is the main driver. A 2020 meta-analysis of GH therapy in adults found that lean mass gains correlate with IGF-1 increases. Hexarelin raises IGF-1 briefly. CJC-1295 raises it for longer. That points to CJC-1295 as the stronger candidate for lean mass, on paper.
Where the active research is
Current studies focus on combination protocols. Researchers pair a GHRP like Hexarelin with a GHRH analogue like CJC-1295 to mimic natural pulses. A 2021 animal study found that the combination increased muscle fiber cross-sectional area more than either peptide alone. Human data is still thin.
Another active area is recovery from tendon and ligament injuries. A 2023 pilot study in recreational runners looked at CJC-1295 plus BPC-157 after Achilles strain. The combination group returned to running faster than the control group. The study was small, around 20 participants, but it fits the track and field rehab interest.
Hexarelin research is moving toward cardioprotection. A 2022 trial in heart failure patients showed improved cardiac output with twice daily Hexarelin. That is not a muscle growth finding, but it suggests the peptide has systemic effects beyond GH release. Athletes should not extrapolate from cardiac data to performance.
Where the gaps are
No large human trial has directly compared Hexarelin and CJC-1295 for lean mass. Most data comes from rodents or short-term metabolic studies. The longest human study of CJC-1295 lasted 12 weeks. Hexarelin human studies rarely exceed two weeks. That makes long-term safety unclear.
Desensitization is a known issue with Hexarelin. A 2018 study found that twice daily dosing for 14 days reduced the GH response by roughly 40 percent. CJC-1295 does not show the same rapid tolerance, but its continuous elevation may downregulate receptors over months. Neither peptide is approved for human use. Both are research chemicals.
For track and field athletes, the rehab and recovery peptide literature is still immature. Most studies use small samples and short windows. The gap between animal data and human performance is wide. Anyone considering these compounds should treat them as experimental, not as established ergogenic aids.
Common questions
Does Hexarelin build more muscle than CJC-1295?
Published research does not support that. Hexarelin creates a sharp GH spike, which may help fat oxidation but does not sustain IGF-1. CJC-1295 keeps IGF-1 elevated for days, which is more relevant for lean tissue accrual. Animal studies show greater muscle growth with continuous GH elevation than with intermittent spikes. Human data is too limited for a definitive answer.
Can you stack Hexarelin and CJC-1295?
Yes, and that is the most common research protocol. The GHRP plus GHRH combination mimics the natural pulsatile pattern. A 2021 animal study found additive effects on muscle fiber size. Human trials are lacking. The main risk is overstimulation of the pituitary over time. Cycling and monitoring IGF-1 levels are standard precautions in research settings.
What is the typical research dose for each peptide?
Hexarelin is usually studied at 100 to 200 mcg per injection, two to three times daily. CJC-1295 is studied at 1 to 2 mg per week, often split into two doses. These are research ranges from published studies, not recommendations. Individual response varies widely. Desensitization is a concern with Hexarelin at higher frequencies.
Which peptide is better for tendon recovery?
CJC-1295 has more indirect support for connective tissue. Sustained IGF-1 elevation stimulates collagen synthesis in fibroblasts. A 2023 pilot study combined CJC-1295 with BPC-157 for Achilles strain and found faster return to running. Hexarelin has no direct tendon data. BPC-157 is the primary healing peptide in that stack.
Are these peptides legal for athletes?
No. Both Hexarelin and CJC-1295 are prohibited by the World Anti-Doping Agency. They appear on the S2 category as peptide hormones and growth factors. Athletes subject to testing should avoid them entirely. This is an editorial discussion of published research. It is not a treatment plan.